Market Research Report
Anti-obesity Prescription Drugs Market Research Report by Drug Class, by Age Group, by Distribution Channel, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
|Anti-obesity Prescription Drugs Market Research Report by Drug Class, by Age Group, by Distribution Channel, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19|
Published: June 1, 2021
Content info: 192 Pages
Delivery time: 1-2 business days
The Global Anti-obesity Prescription Drugs Market size was estimated at USD 4,965.81 Million in 2020 and expected to reach USD 5,342.71 Million in 2021, at a Compound Annual Growth Rate (CAGR) 7.92% to reach USD 7,848.73 Million by 2026.
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Anti-obesity Prescription Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the Anti-obesity Prescription Drugs Market was studied across Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate.
Based on Age Group, the Anti-obesity Prescription Drugs Market was studied across Adult and Pediatric.
Based on Distribution Channel, the Anti-obesity Prescription Drugs Market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Based on Geography, the Anti-obesity Prescription Drugs Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-obesity Prescription Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-obesity Prescription Drugs Market, including 7TM Pharma A/S, Akrimax Pharmaceuticals Inc, Alizyme PLC, Arena Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Co, C.H. Boehringer Sohn AG & Ko. KG, Cadila Healthcare Limited, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Norgine BV, Novo Nordisk A/s, Orexigen Therapeutics, Inc, Orexigen Therapeutics, Inc., Pfizer Inc,, Rhythm Pharmaceuticals, Inc., Shionogi USA Inc, Takeda Pharmaceutical Company Limited, Vivus Inc, VIVUS, Inc, and Zafgen Inc.
The report provides insights on the following pointers:
The report answers questions such as: